Fostemsavir: A new treatment option for extensive HIV drug resistance
From TheBodyPro… As 2020 draws to a close, we asked David Alain Wohl, M.D., a professor of medicine in the Division of Infectious Diseases at the University of North Carolina and a highly respected HIV clinician-researcher, to take stock of the year’s most momentous research developments and other critical events. In this exclusive series of articles, […]
New cause of inflammation in people with HIV identified
From MedicalXpress.com… While current antiretroviral treatments for HIV are highly effective, data has shown that people living with HIV appear to experience accelerated aging and have shorter lifespans—by up to five to 10 years—compared to people without HIV. These outcomes have been associated with chronic inflammation, which could lead to the earlier onset of age-associated […]
Protect yourself from the Flu: Important info for people with HIV
From HIV.gov… Getting a flu vaccine during 2020-2021 is more important than ever because of the ongoing COVID-19 pandemic. When you get vaccinated, you reduce your risk of getting sick with flu and possibly being hospitalized or dying from flu. This season, getting a flu vaccine has the added benefit of reducing the overall burden […]
Large NIH Clinical Trial Illuminates Long-Term Health Effects of HIV
From HIV.gov… Initial data from a large NIH-supported clinical trial offer a detailed look at the health status of people aging with HIV around the world. With 7,770 participants enrolled in 12 countries across five continents, the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE ) is evaluating the ability of a statin medication, pitavastatin, to […]
HIV.gov: Introducing the “AHEAD” dashboard
To support the efforts of local partners in ending the HIV epidemic in their communities, the U.S. Department of Health and Human Services (HHS) is announcing the launch of a new tool, AHEAD: America’s HIV Epidemic Analysis Dashboard. What is the AHEAD Dashboard? AHEAD is a data visualization tool created to support the efforts of […]
FDA Approves New HIV Treatment for Patients With Limited Treatment Options
From the FDA… [On July 2, 2020], the U.S. Food and Drug Administration approved Rukobia (fostemsavir), a new type of antiretroviral medication for adults living with HIV who have tried multiple HIV medications and whose HIV infection cannot be successfully treated with other therapies because of resistance, intolerance or safety considerations. “This approval marks a […]
Raltegravir-Based ART Regimens Appear Superior to Efavirenz for Use Among HIV-Positive Pregnant Patients
From AJMC.com… Among the principal reasons for recommending initiating antiretroviral treatment (ART) among pregnant patients who are HIV positive is to prevent transmission of the virus to their unborn children. This number was estimated at 1.3 million pregnant pregnant women, as of 2018. However, optimal treatment regimens remain unclear. An international team of investigators published their study results earlier […]
New Interim NIH Guidelines for people living with HIV regarding the COVID-19 pandemic
From the National Institutes of Health and Human Services… New guidelines have been set by the NIH in regards to persons living with HIV. This interim guidance reviews special considerations for persons with HIV and their health care providers in the United States regarding COVID-19. Information and data on COVID-19 are rapidly evolving. This guidance […]
Does HIV raise risk of coronavirus? Experts weigh in
From Yahoo News… Matthew, 30, keeps an emergency stockpile of his life-saving HIV medication at his home in Sacramento, California. He started building his stash shortly after he was diagnosed six years ago, on the recommendation of people he met through a forum for those living with HIV. Without his once-a-day pill, his viral load […]
Detectable Viral Load Tied to Uptick in Heart Disease Risk in Youth With HIV
From Poz.com… Among young people living with HIV, having a detectable viral load is associated with a slight increase in the risk of cardiovascular disease. Sitaji Gurung, MD, PhD, MPH, of Hunter College at the City University of New York, presented findings from a study of HIV-positive youth 14 to 26 years old at the […]